Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Findings from a phase 1 trial demonstrate that silmitasertib shows potential for the treatment of patients with advanced ...

and efficacy of solnerstotug as both a monotherapy and in combination with Regeneron’s PD-1 inhibitor Libtayo ® (cemiplimab) in patients with advanced solid tumors. Recent updates include ...

Optimal Treatment Response: Three patients achieved partial response ... or in combination with the second-line immunotherapy Libtayo. The company aims to explore further indications and potential ...

Total Libtayo sales came in at $366.9 million ... the late-stage QUASAR study evaluating EYLEA HD for the treatment of patients with macular edema following RVO, including those with central ...